Initial eGFR Changes Predict Response to Tolvaptan in ADPKD.

Mochizuki, Toshio; Matsukawa, Miyuki; Tanaka, Toshiki; Jiang, Huan

Mochizuki, Toshio; Matsukawa, Miyuki; Tanaka, Toshiki; Jiang, Huan.

Affiliation

Mochizuki T; PKD Nephrology Clinic, Tokyo, Japan.
Matsukawa M; Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Osaka, Japan.
Tanaka T; Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
Jiang H; Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey.

Kidney360 ; 5(4): 522-528, 2024 Apr 01.

Article in En | MEDLINE | ID: mdl-38414126

Subject(s)

Antidiuretic Hormone Receptor Antagonists; Glomerular Filtration Rate; Polycystic Kidney, Autosomal Dominant; Tolvaptan; Humans; Tolvaptan/therapeutic use; Polycystic Kidney, Autosomal Dominant/drug therapy; Antidiuretic Hormone Receptor Antagonists/therapeutic use; Glomerular Filtration Rate/drug effects; Male; Female; Adult; Treatment Outcome; Middle Aged

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polycystic Kidney, Autosomal Dominant / Antidiuretic Hormone Receptor Antagonists / Tolvaptan / Glomerular Filtration Rate Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Kidney360 Year: 2024 Document type: Article

Fulltext

XML

PubMed Links

Search on Google